Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H41N5O5 |
Molecular Weight | 563.6877 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N3C(=O)[C@](NC(=O)[C@H]4CN(C)[C@]5([H])CC6=CNC7=C6C(=CC=C7)[C@@]5([H])C4)(O[C@@]23O)C(C)C
InChI
InChIKey=SEALOBQTUQIVGU-QNIJNHAOSA-N
InChI=1S/C31H41N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,14,16-17,19,21,23-24,26,32,40H,7,10-13,15H2,1-5H3,(H,33,37)/t19-,21-,23-,24+,26+,30-,31+/m1/s1
DescriptionSources: https://www.drugs.com/cdi/hydergine.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2869188 | https://www.ncbi.nlm.nih.gov/pubmed/4205319 | https://www.ncbi.nlm.nih.gov/pubmed/14350151 | https://www.ncbi.nlm.nih.gov/pubmed/17941060
Sources: https://www.drugs.com/cdi/hydergine.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2869188 | https://www.ncbi.nlm.nih.gov/pubmed/4205319 | https://www.ncbi.nlm.nih.gov/pubmed/14350151 | https://www.ncbi.nlm.nih.gov/pubmed/17941060
Dihydroergocornine is an ergot alkaloid, one of the three components of ergoloid (trade name Hydergine). Dihydroergocornine (as the component of Ergoloid mesylates) has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), as well as to aid in recovery after stroke. There is no specific evidence which clearly establishes the mechanism by which Hydergine® (ergoloid mesylates) preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency. Hydergine may stimulates dopaminergic and serotonergic receptors and blocks alpha-adrenoreceptors.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2869188 |
|||
Target ID: CHEMBL265 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2869188 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Hydergine Approved UseUnknown Launch Date1977 |
|||
Sources: https://www.drugs.com/pro/hydergine.html |
Primary | Hydergine Approved UseUnknown Launch Date1977 |
||
Primary | Hydergine Approved UseUnknown Launch Date1977 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.04 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROERGOCRISTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.04 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROERGOCRYPTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.04 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROERGOCORNINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.98 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXY-DIHYDROERGOCORNIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.53 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXY-DIHYDROERGOCRYPTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.3 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17941060/ |
27 mg single, oral dose: 27 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXY-DIHYDROERGOCRISTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/hydergine.html
1 mg of ergoloid mesylates three times daily.
1 mg of ergoloid mesylates contains: dihydroergocornine mesylate 0.333 mg, dihydroergocristine mesylate 0.333 mg, and dihydroergocryptine (dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine in the proportion of 2:1) mesylate 0.333 mg,
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17941060
Biotransformation assays were performed in incubates of rat liver microsomes. Dihydroergotoxine alkaloids in CH3CN–H2O (1:1, v/v) were individually added (30 mm, final concentration) to cold Sorensen buffer 0.1 m pH 7.4 containing the liver enzyme preparation (5mgprot/ml), MgCl2 (10mm), glucose 6-phosphate (10mm), NADP (0.5mm) and glucose 6-phosphate dehydrogenase (1 U/ml) in a total volume of 500 ml. Blank and control incubates were performed similarly, except by adding the buffer solution instead of the drug and NADPH regenerating system, respectively. After incubation at 378C for 30 min, the reactions were terminated by the addition of 50 ml NaOH 0.1m, and vortex-mixing (30 s) with 4ml of diethyl ether. After 15 min at -80C, the upper organic layers were separated and concentrated under a gentle N2 stream.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB13584MIG
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
25447-65-8
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
DB11273
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
100000079783
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
246-992-0
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
DIHYDROERGOCORNINE
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
3415
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
IK4C1OC8NE
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
3184
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
C75936
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
168871
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
59909
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
IK4C1OC8NE
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY | |||
|
DTXSID1044013
Created by
admin on Fri Dec 15 15:43:16 GMT 2023 , Edited by admin on Fri Dec 15 15:43:16 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD